LGP2 Antibody (C-9): sc-373827

LGP2 Antibody (C-9) is a mouse monoclonal IgG2b kappa light chain antibody that detects LGP2 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). LGP2 (C-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. LGP2, also known as probable ATP-dependent RNA helicase DHX58, is a 678 amino acid protein that plays a crucial role in the innate immune response to viral infections. Specifically, LGP2 functions as a negative regulator of host defenses by binding to double-stranded RNA (dsRNA) generated during viral replication, which is essential for the immune system′s ability to detect and respond to viral threats. By interacting with RIG-I, a key signaling protein in the immune response against viruses such as hepatitis C virus (HCV), LGP2 prevents RIG-I multimerization, thereby inhibiting RIG-I-mediated signaling pathways that would otherwise activate antiviral responses. This regulatory mechanism is vital for maintaining a balanced immune response, as excessive activation can lead to tissue damage and autoimmune disorders. Localized in the cytoplasm, LGP2 contains one helicase ATP-binding domain and one helicase C-terminal domain, which are critical for its function in RNA unwinding and immune modulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LGP2 Antibody (C-9) References:

1. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.  |  Yoneyama, M., et al. 2005. J Immunol. 175: 2851-8. PMID: 16116171
2. RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2.  |  Komuro, A. and Horvath, CM. 2006. J Virol. 80: 12332-42. PMID: 17020950
3. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2.  |  Saito, T., et al. 2007. Proc Natl Acad Sci U S A. 104: 582-7. PMID: 17190814
4. Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response.  |  Murali, A., et al. 2008. J Biol Chem. 283: 15825-33. PMID: 18411269
5. LGP2 downregulates interferon production during infection with seasonal human influenza A viruses that activate interferon regulatory factor 3.  |  Malur, M., et al. 2012. J Virol. 86: 10733-8. PMID: 22837208
6. Identification of an LGP2-associated MDA5 agonist in picornavirus-infected cells.  |  Deddouche, S., et al. 2014. Elife. 3: e01535. PMID: 24550253
7. Foot-and-mouth disease virus infection inhibits LGP2 protein expression to exaggerate inflammatory response and promote viral replication.  |  Zhu, Z., et al. 2017. Cell Death Dis. 8: e2747. PMID: 28406479
8. LGP2 virus sensor regulates gene expression network mediated by TRBP-bound microRNAs.  |  Takahashi, T., et al. 2018. Nucleic Acids Res. 46: 9134-9147. PMID: 29939295
9. LGP2 virus sensor enhances apoptosis by upregulating apoptosis regulatory genes through TRBP-bound miRNAs during viral infection.  |  Takahashi, T., et al. 2020. Nucleic Acids Res. 48: 1494-1507. PMID: 31799626
10. Viral RNA recognition by LGP2 and MDA5, and activation of signaling through step-by-step conformational changes.  |  Duic, I., et al. 2020. Nucleic Acids Res. 48: 11664-11674. PMID: 33137199
11. K63-linked polyubiquitination of LGP2 by Riplet regulates RIG-I-dependent innate immune response.  |  Kouwaki, T., et al. 2023. EMBO Rep. 24: e54844. PMID: 36515138
12. Unraveling blunt-end RNA binding and ATPase-driven translocation activities of the RIG-I family helicase LGP2.  |  Lee, KY., et al. 2024. Nucleic Acids Res. 52: 355-369. PMID: 38015453

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LGP2 Antibody (C-9) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-LGP2 Antibody (C-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LGP2 Antibody (C-9) Specifications

Alternate Product Name: LGP2

Product Clone Name: C-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 520-678

Epitope Target: LGP2

Epitope Species: human

Product Reactivity/Detection: LGP2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for LGP2 Antibody (C-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin